Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.38 USD
Change Today -0.02 / -0.83%
Volume 533.9K
SYN On Other Exchanges
As of 4:15 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

synthetic biologics inc (SYN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/15/15 - $4.32
52 Week Low
10/16/14 - $1.34
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

synthetic biologics inc (SYN) Related Bloomberg News

View More Bloomberg News

synthetic biologics inc (SYN) Related Businessweek News

No Related Businessweek News Found

synthetic biologics inc (SYN) Details

Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection; an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C); and a monoclonal antibody combination for the treatment of Pertussis. The company is also developing a Phase II oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. It has collaboration agreements with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; sublicense agreement with Meda AB; and license agreements with McLean Hospital and The Regents of University of California. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetics Biologics, Inc. in February 2012. Synthetics Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.

20 Employees
Last Reported Date: 08/10/15
Founded in 2001

synthetic biologics inc (SYN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $499.0K
Compensation as of Fiscal Year 2014.

synthetic biologics inc (SYN) Key Developments

Synthetic Biologics Inc. Appoints Raymond Stapleton as Senior Vice President of Manufacturing

Synthetic Biologics Inc. announced that Raymond D. Stapleton, PhD, has joined the company as Senior Vice President of Manufacturing. Dr. Stapleton will lead the manufacturing team as the company begins to prepare for late-stage clinical trials for its irritable bowel syndrome with constipation (IBS-C). Dr. Stapleton is a pharmaceutical and biotechnology executive with over 15 years of experience at Merck & Co. Inc., in manufacturing, operations, quality, science, technology, engineering and process development. He most recently served as Executive Director, Global Vaccine Technology and Engineering.

Synthetic Biologics Initiates SYN-004 Phase 2b Proof-Of-Concept Clinical Trial

Synthetic Biologics Inc. reported the initiation of its SYN-004 Phase 2b proof-of-concept clinical trial. The clinical trial is intended to evaluate the effectiveness of SYN-004 to prevent C. difficile infection (CDI), C. difficile associated diarrhea (CDAD) and antibiotic-associated diarrhea (AAD) in patients hospitalized for a lower respiratory tract infection and receiving intravenous (IV) ceftriaxone. C. difficile is a type of hospital acquired infection and is frequently associated with IV antibiotic treatment. Beta-lactam antibiotics are a mainstay in hospital infection management, and include commonly used penicillin and cephalosporin antibiotics, such as ceftriaxone. However, antibiotics have the potential to cause harmful effects within the gastrointestinal (GI) tract including disruption of the natural balance of the gut microbiome, leading to 1.1 million CDIsi and 30,000 C. difficile-related deathsii in the United States each year. SYN-004 is Synthetic Biologics' oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of CDI, AAD and emergence of antibiotic-resistant organisms. The Phase 2b, parallel-group, double-blind, placebo-controlled study of SYN-004 is expected to enroll approximately 370 patients at up to 75 global clinical sites. Patients age 50 years and older, hospitalized for a lower respiratory tract infection, are expected to be randomized 1:1 into two groups, and receive either SYN-004 or placebo during the standard of care regimen of ceftriaxone (with or without a macrolide). The primary objectives of this clinical trial are to evaluate the effectiveness of SYN-004 to prevent CDIs and CDAD. The secondary objective of this clinical trial is to evaluate the effectiveness of SYN-004 to prevent AAD.

Synthetic Biologics Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Synthetic Biologics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $9,730,000 compared to $4,651,000 a year ago. Net loss attributable to the company and subsidiaries was $13,623,000 or $0.19 per basic and diluted share compared to $4,556,000 or $0.08 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $17,937,000 compared to $8,490,000 a year ago. Net loss attributable to the company and subsidiaries was $25,981,000 or $0.14 per basic and diluted share compared to $8,394,000 or $0.36 per basic and diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SYN:US $2.38 USD -0.02

SYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SYN.
View Industry Companies

Industry Analysis


Industry Average

Valuation SYN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNTHETIC BIOLOGICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at